Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge

被引：40

作者：

Rajagopalan, Arvind ^{[1
]}

Sathananthan, Dharshan ^{[1
,2
]}

An, Yoon-Kyo ^{[3
]}

Van De Ven, Lucinda ^{[1
]}

Martin, Serena ^{[1
]}

Fon, James ^{[1
]}

Costello, Samuel P. ^{[1
,2
]}

Begun, Jakob ^{[3
,4
]}

Bryant, Robert V. ^{[1
,2
]}

机构：

[1] Queen Elizabeth Hosp, Dept Gastroenterol, IBD Serv, Adelaide, SA, Australia

[2] Univ Adelaide, Sch Med, Fac Hlth Sci, Adelaide, SA, Australia

[3] Mater Hosp, Dept Gastroenterol, Brisbane, Qld, Australia

[4] Univ Queensland, Fac Med, Brisbane, Qld, Australia

来源：

JGH OPEN | 2020年 / 4卷 / 02期

关键词：

gastrointestinal ultrasound; inflammatory bowel disease; inflammatory bowel disease imaging; patient perceptions; point-of-care ultrasound;

D O I：

10.1002/jgh3.12268

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background and Aim: Objective monitoring of disease activity is integral to therapeutic decision-making in inflammatory bowel disease (IBD). Data are sparse on patients' perspectives of tools used to monitor disease activity in IBD. To evaluate patients' perspectives of gastrointestinal ultrasound (GIUS) performed during routine IBD clinical care, along with its impact on IBD-specific knowledge. Methods: Patients with a formal diagnosis of IBD who underwent GIUS at two tertiary IBD services between March 2017 and January 2019 participated in this prospective study. Participants completed a questionnaire measuring the acceptability, tolerability, and usefulness of GIUS using a visual analogue scale (VAS) from 0 (disagree) to 10 (strongly agree). Comparative acceptability of IBD monitoring tools and the impact of GIUS on IBD-specific knowledge was measured. Results: A total of 121 participants completed the questionnaire, with a mean age of 42 years (range 17-78), 54 (45%) males, and 79 (65%) Crohn's disease patients. In the overall population, GIUS was scored as highly acceptable for monitoring IBD (mean 9.20 +/- 1.37) compared to colonoscopy (7.94 +/- 2.30), stool sampling (8.17 +/- 1.96), blood sampling (8.87 +/- 1.62), and imaging (8.67 +/- 1.60); P < 0.01 for each comparison. GIUS caused little patient discomfort (1.88 +/- 1.83), and 98 (81%) participants ranked GIUS as their preferred IBD monitoring tool. GIUS also improved patients' overall IBD-specific knowledge (VAS IBD-specific knowledge 7.96 +/- 1.92), including their understanding of the need for medical therapy and disease extent. Conclusion: GIUS is a highly acceptable and well-tolerated tool for monitoring disease activity in IBD patients. GIUS is preferred by patients and enhances IBD-specific knowledge.

引用

页码：267 / 272

页数：6

共 33 条

[21] Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease [J].

Panes, J. ;

Bouzas, R. ;

Chaparro, M. ;

Garcia-Sanchez, V. ;

Gisbert, J. P. ;

Martinez de Guerenu, B. ;

Mendoza, J. L. ;

Paredes, J. M. ;

Quiroga, S. ;

Ripolles, T. ;

Rimola, J. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (02) :125-145

[22]

PARENTE FA, 2006, GUT, V55

[23] Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis ?: A Prospective Study [J].

Parente, Fabrizio ;

Molteni, Mirko ;

Marino, Barbara ;

Colli, Agostino ;

Ardizzone, Sandro ;

Greco, Salvatore ;

Sampietro, Gianluca ;

Foschi, Diego ;

Gallus, Silvano .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1150-1157

[24] Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target [J].

Peyrin-Biroulet, L. ;

Sandborn, W. ;

Sands, B. E. ;

Reinisch, W. ;

Bemelman, W. ;

Bryant, R. V. ;

D'Haens, G. ;

Dotan, I. ;

Dubinsky, M. ;

Feagan, B. ;

Fiorino, G. ;

Gearry, R. ;

Krishnareddy, S. ;

Lakatos, P. L. ;

Loftus, E. V., Jr. ;

Marteau, P. ;

Munkholm, P. ;

Murdoch, T. B. ;

Ordas, I. ;

Panaccione, R. ;

Riddell, R. H. ;

Ruel, J. ;

Rubin, D. T. ;

Samaan, M. ;

Siegel, C. A. ;

Silverberg, M. S. ;

Stoker, J. ;

Schreiber, S. ;

Travis, S. ;

Van Assche, G. ;

Danese, S. ;

Panes, J. ;

Bouguen, G. ;

O'Donnell, S. ;

Pariente, B. ;

Winer, S. ;

Hanauer, S. ;

Colombel, J. -F. .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (09) :1324-1338

[25] Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis [J].

Rutter, M ;

Saunders, B ;

Wilkinson, K ;

Rumbles, S ;

Schofield, G ;

Kamm, M ;

Williams, C ;

Price, A ;

Talbot, I ;

Forbes, A .

GASTROENTEROLOGY, 2004, 126 (02) :451-459

[26]

SATHANANTHAN D, 2018, AUST GASTROENTEROL W, V33, pS 2, DOI DOI 10.1111/JGH.14395:112

[27] The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications [J].

Satsangi, J. ;

Silverberg, M. S. ;

Vermeire, S. ;

Colombel, J-F .

GUT, 2006, 55 (06) :749-753

[28] Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease [J].

Schnitzler, Fabian ;

Fidder, Herma ;

Ferrante, Marc ;

Noman, Maja ;

Arijs, Ingrid ;

Van Assche, Gert ;

Hoffman, Ilse ;

Van Steen, Kristel ;

Vermeire, Severine ;

Rutgeerts, Paul .

INFLAMMATORY BOWEL DISEASES, 2009, 15 (09) :1295-1301

[29] Modifiable Factors Associated with Nonadherence to Maintenance Medication for Inflammatory Bowel Disease [J].

Selinger, Christian P. ;

Eaden, Jayne ;

Jones, D. Brian ;

Katelaris, Peter ;

Chapman, Grace ;

McDonald, Charles ;

Smith, Paul ;

Lal, Simon ;

Leong, Rupert W. ;

McLaughlin, John ;

Robinson, Andrew .

INFLAMMATORY BOWEL DISEASES, 2013, 19 (10) :2199-2206

[30] Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease [J].

Selinger, Christian P. ;

Robinson, Andrew ;

Leong, Rupert W. .

EXPERT OPINION ON DRUG SAFETY, 2011, 10 (06) :863-870

← 1 2 3 4 →